In this bonus episode of FierceBiotech Radio, John Carroll sits down with Bloomberg Intelligence analyst Asthika Goonewardene to discuss the results of an informal survey in which readers weighed in on whether the unprecedented bull market for biotech is sustainable or has transformed into a fragile bubble ready to pop (watch the video here). Then, FiercePharma's Carly Helfand discusses #FierceMadness, a single-elimination tournament of drug names going on over at FiercePharmaMarketing.
Download the episode on iTunes or Stitcher, or listen below--and be sure to subscribe. Let us know what you think by dropping a line to firstname.lastname@example.org. And if you missed this week's talk with EP Vantage's Amy Brown, you can find it here.